Q3 2020 Compugen Ltd Earnings Call

Based on the translation of our considerable scientific knowledge of the denim X fees, which we continue to expand in our company.

In line with Dave you know.

Our last call I discussed the growing body of evidence that supports the distinct nature of Pierre Aegean TIGIT.

Although these are two complimentary pathways, the two targets buying differently guns how.

Have differing levels of expression and dominance across tumor type and have differential expression across immune cell types.

Further supports their non redundant roles and our overall drug combination hypotheses and strategy.

As we're continually working to drive a deeper understanding of the denim axes in cancer immunotherapy.

In order to further support the strong scientific foundation that has been integral to our efforts and continuously feed our clinical strategy.

We were pleased to present, new research data at the 2020 TV therapies digital summit held at the end of October.

This research further supports the distinct biology of Tdrs Gn TIGIT antibody logical rationale of our combination strategy to maximize clinical responses.

These data show that pediatric Gi is expressed on Tim like memory T cells or T.S.C.M. sales.

This can differentiate into effector T cells, which can directly eliminate tumor cells.

Notably these results, indicating Pete here a gene expression on these shows.

Ed to deprive belief the ticket and PD, one where the main checkpoints expressed on pieces.

He is the M. R of growing interest in the fit for their possible role in response to immune checkpoint blockade.

To complement these findings we also reported that PV or into the ligand of PBF energy is expressed on specialized sales involved in T cell proliferation activation and infiltration into tumors.

And he's also expressed in PDL, one no less inflamed tumors.

Specifically PPL two is abundantly expressed across a dendritic cell types, which are associated with efficient T cell activation as well as their shearling freed structures into more beds, where local t. cell priming occur and which have been previously shown to.

Be associated with response to cancer immunotherapy.

These data demonstrate for the first time that in addition to teach it and PD one PD.

<unk> antibody.

The initiation of this trial was a particularly meaningful milestone for competition.

As it marks the clinical evaluation of our underlying signs.

While combinations of teaching and PD, one inhibitors are being evaluated by others.

We are uniquely addressing what we believe is a key component in the denim X fees, we believe the distinguished Chinese blockade of pediatric Gi TIGIT NPD one.

He did grow over the past month and were pleased to see the clinical validation of these new checkpoint pathway.

We believe these data provide important validation of our discovery platform is.

As we were among the first groups to discover TIGIT.

It also increases our confidence in our overall hypotheses and triple pathway blockade study.

On treating Io naive first line head and neck squamous cell carcinoma patients with a combination of bay one nine.